Skip to main content

Table 3 Outcomes and toxicity

From: Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma

Patient Site treated Follow-up (months) RECIST score Clinical Outcome FFDM (months) Site of progression Acute toxicity Grade Late toxicity Grade
1 Liver 25.5 PR DOD 9.6 Liver (other sites), paracaval LN Fatigue 1 GI pain, diarrhea 1
  Liver 15.7 PR DOD 6.1 Paraaortic LN Nausea 1 GI pain, diarrhea 1
  Lymph node 15.7 PR DOD 6.1 Paraaortic LN Nausea 1 GI pain, diarrhea 1
2 Liver 17.2 SD DOD 13.1 Liver (other sites) Nausea 2 Biliary stenosis 3
3 Liver 8.6 PR DOD 1.6 Liver (other sites) Fatigue 1 GI pain 2
4 Liver 2.4 SD DOC - - GI pain 1 - -
5 Liver 21.8 CR NED - - Nausea 2 - -
6 Liver 19.8 PR DOC - - Nausea 2 Liver failure 5
7 Liver 5.9 SD DOD 3.8 Mesenteric LN GI pain 2 GI pain 2
8 Liver 11.3 SD AWD 1.8 Liver (other sites), lung Nausea, GI pain 2 GI pain 2
9 Adrenal 11.3 CR AWD 6.5 Liver - - - -
10 Liver 3.1 CR NED - - Nausea 2 - -
  1. Abbreviations: RECIST Response Evaluation Criteria in Solid Tumors, FFDM Freedom from distant progression, PR Partial response, SD Stable disease, CR Complete response, DOD Dead of disease, DOC Dead of other causes, NED No evidence of disease, AWD Alive with disease, LN Lymph node, GI Gastrointestinal.